Indinavir: Chemoinformatics prediction for hepatitis C virus inhibitor property

How to cite this article:
Joob B, Wiwanitkit V. Indinavir: Chemoinformatics prediction for hepatitis C virus inhibitor property. Ann Trop Med Public Health 2016;9:197-8

 

How to cite this URL:
Joob B, Wiwanitkit V. Indinavir: Chemoinformatics prediction for hepatitis C virus inhibitor property. Ann Trop Med Public Health [serial online] 2016 [cited 2020 Sep 21];9:197-8. Available from: https://www.atmph.org/text.asp?2016/9/3/197/181652

Dear Sir,

The human immunodeficiency virus (HIV) infection is a public health problem worldwide. The use of antiretroviral therapy is the standard management of HIV infection. There are many new anti-HIV drugs, and indinavir is one of those drugs.[1] An interesting concern in using anti-HIV drugs is the effect on other concurrent infection, especially for hepatitis C virus (HCV). In a recent report, the change of anti-HIV regimen is proposed to cause clearance of HCV.[2] Here, the authors use standard biochemoinformatics technique, namely, “General Unrestricted Structure-Activity Relationships – GUSAR” for assessment of the inhibitor effect of indinavir on HCV. This technique is used in some previous publications.[3] According to the prediction modeling, indinavir can have the inhibiting effect on HCV without genotoxicity inductor property. Indeed, the management of concurrent HIV and HCV infection requires targeting on both viruses. Matthews and Dore noted that “new therapies, including HCV protease and polymerase inhibitors, are in development and may widen therapeutic options for HIV–HCV-coinfected individuals.”[4] Nevertheless, if a single antiviral drug can be helpful for managing both diseases, it will be favorable. Based on the present informatics study, indinavir might be helpful as mentioned. However, this needs further clinical study for verification.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

 

1.
Lacy MK, Abriola KP. Indinavir: A pharmacologic and clinical review of a new HIV protease inhibitor. Conn Med 1996;60:723-7.
2.
Endo T, Fujimoto K, Nishio M, Yamamoto S, Obara M, Sato N, et al. Case report: Clearance of hepatitis C virus after changing the HAART regimen in a patient infected with hepatitis C virus and the human immunodeficiency virus. J Med Virol 2009;81:979-82.
3.
Masand VH, Mahajan DT, Patil KN, Hadda TB, Youssoufi MH, Jawarkar RD, et al. Optimization of antimalarial activity of synthetic prodiginines: QSAR, GUSAR, and CoMFA analyses. Chem Biol Drug Des 2013;81:527-36.
4.
Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol 2008;23:1000-8.

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/1755-6783.181652

Paul Mies has now been involved with test reports and comparing products for a decade. He is a highly sought-after specialist in these areas as well as in general health and nutrition advice. With this expertise and the team behind atmph.org, they test, compare and report on all sought-after products on the Internet around the topics of health, slimming, beauty and more. The results are ultimately summarized and disclosed to readers.

LEAVE A REPLY

Please enter your comment!
Please enter your name here